HK1209418A1 - Process for the preparation of c-fms kinase inhibitors c-fms - Google Patents
Process for the preparation of c-fms kinase inhibitors c-fmsInfo
- Publication number
- HK1209418A1 HK1209418A1 HK15110017.1A HK15110017A HK1209418A1 HK 1209418 A1 HK1209418 A1 HK 1209418A1 HK 15110017 A HK15110017 A HK 15110017A HK 1209418 A1 HK1209418 A1 HK 1209418A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fms
- preparation
- kinase inhibitors
- fms kinase
- inhibitors
- Prior art date
Links
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 title 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680446P | 2012-08-07 | 2012-08-07 | |
PCT/US2013/053602 WO2014025679A1 (en) | 2012-08-07 | 2013-08-05 | Process for the preparation of c-fms kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209418A1 true HK1209418A1 (en) | 2016-04-01 |
Family
ID=48980367
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110017.1A HK1209418A1 (en) | 2012-08-07 | 2015-10-14 | Process for the preparation of c-fms kinase inhibitors c-fms |
HK15111400.4A HK1210616A1 (en) | 2012-08-07 | 2015-11-19 | Process for the preparation of c-fms kinase inhibitors c-fms |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111400.4A HK1210616A1 (en) | 2012-08-07 | 2015-11-19 | Process for the preparation of c-fms kinase inhibitors c-fms |
Country Status (13)
Country | Link |
---|---|
US (2) | US9029352B2 (xx) |
EP (2) | EP3091006B1 (xx) |
JP (1) | JP6290884B2 (xx) |
CN (2) | CN107266405A (xx) |
AR (2) | AR092070A1 (xx) |
AU (2) | AU2013299926B2 (xx) |
ES (2) | ES2658773T3 (xx) |
HK (2) | HK1209418A1 (xx) |
IN (1) | IN2015DN00660A (xx) |
JO (2) | JOP20180012A1 (xx) |
TW (2) | TWI608004B (xx) |
UY (1) | UY34972A (xx) |
WO (1) | WO2014025679A1 (xx) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201811326A (zh) | 2016-07-18 | 2018-04-01 | 比利時商健生藥品公司 | 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之鹽形式 |
TWI752980B (zh) * | 2016-07-18 | 2022-01-21 | 比利時商健生藥品公司 | 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型 |
JP6831558B2 (ja) * | 2016-08-23 | 2021-02-17 | 株式会社Hbcフナト | 脳機能改善組成物 |
CN110636861B (zh) * | 2017-03-03 | 2022-07-08 | 詹森生物科技公司 | 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法 |
WO2020222109A1 (en) | 2019-05-02 | 2020-11-05 | Janssen Biotech, Inc. | Csf-1/csf-1r gene set |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2466420A (en) | 1947-11-26 | 1949-04-05 | Eastman Kodak Co | Ketene condensation products with aldehydes |
US3226394A (en) | 1964-06-16 | 1965-12-28 | Shulton Inc | Pyridylethylated anthranilamides and derivatives thereof |
CH504416A (de) | 1966-12-05 | 1971-03-15 | Ciba Geigy Ag | Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen |
US4551540A (en) | 1983-01-17 | 1985-11-05 | Borg-Warner Chemicals, Inc. | Substituted 2,5-dimethylpyrroles |
US5190541A (en) | 1990-10-17 | 1993-03-02 | Boston Scientific Corporation | Surgical instrument and method |
WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
US5474765A (en) | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5593992A (en) | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
EP0785937A1 (en) | 1994-10-14 | 1997-07-30 | Smithkline Beecham Plc | 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials |
EP0822788B1 (en) | 1995-04-19 | 2002-09-04 | Schneider (Usa) Inc. | Drug release coated stent |
US6117432A (en) | 1995-04-20 | 2000-09-12 | Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) | Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
DE69620445T2 (de) | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica N.V., Beerse | (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5702390A (en) | 1996-03-12 | 1997-12-30 | Ethicon Endo-Surgery, Inc. | Bioplar cutting and coagulation instrument |
US5900484A (en) * | 1996-09-18 | 1999-05-04 | Lonza Ag | Process for the preparation of arylamides of heteroaromatic carboxylic acids |
CA2262676A1 (en) | 1996-08-09 | 1998-02-19 | Merck & Co., Inc. | Stereoselective deoxygenation reaction |
CN1095845C (zh) | 1996-12-20 | 2002-12-11 | "塔比法尔"有限责任公司 | 制取冻干的1β,10β-环氧-13-二甲基氨基-愈创-3(4)-烯-6,12-内酯盐酸盐的方法和装置 |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
TR199902606T2 (xx) | 1997-04-25 | 2000-07-21 | Janssen Pharmaceutica N.V. | Farnesil transferaz� engelleyici kinazolinonlar. |
TW491872B (en) | 1997-05-27 | 2002-06-21 | Ciba Sc Holding Ag | Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin |
US6100254A (en) | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
WO1999045712A1 (en) | 1998-03-05 | 1999-09-10 | Formula One Administration Limited | Data communication system |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
JP2002520324A (ja) | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
BR9913315A (pt) | 1998-08-27 | 2001-05-22 | Pfizer Prod Inc | Derivados de quinolin-2-ona úteis como agentes anticâncer |
ATE321037T1 (de) | 1998-08-27 | 2006-04-15 | Pfizer Prod Inc | Als antikrebsmittel verwendbare alkinyl- substituierte chinolin-2-on-derivate |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
KR100818541B1 (ko) | 1998-12-23 | 2008-04-02 | 얀센 파마슈티카 엔.브이. | 1,2-어닐링된 퀴놀린 유도체 |
AU779008C (en) | 1999-01-11 | 2005-06-30 | Princeton University | High affinity inhibitors for target validation and uses thereof |
CZ302788B6 (cs) | 1999-04-15 | 2011-11-09 | Bristol-Myers Squibb Company | ´N-(2-Chlor-6-methylfenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolkarboxamid, jeho použití a farmaceutický prostredek s jeho obsahem |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
KR100816572B1 (ko) | 1999-04-28 | 2008-03-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 항-vegf 항체 및 이를 포함하는 약제학적 조성물 |
US6346625B1 (en) | 1999-06-23 | 2002-02-12 | Astrazeneca Ab | Protein kinase inhibitors |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
CA2394727A1 (en) | 1999-12-28 | 2001-07-05 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
FR2803592A1 (fr) | 2000-01-06 | 2001-07-13 | Aventis Cropscience Sa | Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant. |
US6558385B1 (en) | 2000-09-22 | 2003-05-06 | Tissuelink Medical, Inc. | Fluid-assisted medical device |
US6692491B1 (en) | 2000-03-24 | 2004-02-17 | Scimed Life Systems, Inc. | Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6960590B2 (en) | 2000-10-17 | 2005-11-01 | Merck & Co. Inc. | Orally active salts with tyrosine kinase activity |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
DK1441737T3 (da) | 2001-10-30 | 2006-11-13 | Novartis Ag | Staurosporin-derivater som inhibitorer af FLT3-receptor-tyrosinkinase-aktivitet |
DK1458713T3 (da) | 2001-12-27 | 2005-10-31 | Theravance Inc | Indolinonderivater anvendelige som proteinkinaseinhibitorer |
CN100558715C (zh) | 2002-05-23 | 2009-11-11 | 西托匹亚有限公司 | 蛋白激酶抑制剂 |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7304071B2 (en) | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF |
AU2003258491A1 (en) | 2002-09-05 | 2004-03-29 | Neurosearch A/S | Amide derivatives and their use as chloride channel blockers |
KR20110050745A (ko) | 2002-10-03 | 2011-05-16 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
US20080207617A1 (en) | 2002-10-29 | 2008-08-28 | Kirin Beer Kabushiki Kaisha | Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same |
JP2006511616A (ja) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
BRPI0409136A (pt) | 2003-04-09 | 2006-04-25 | Japan Tobacco Inc | composto heteroaromático pentacìclico e uso medicinal do mesmo |
US20050113566A1 (en) | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
WO2004096795A2 (en) | 2003-04-25 | 2004-11-11 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
US7427683B2 (en) | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
AU2004261627C1 (en) | 2003-07-28 | 2009-02-05 | Smithkline Beecham Corporation | Cycloalkylidene compounds as modulators of estrogen receptor |
WO2005040139A2 (en) | 2003-10-23 | 2005-05-06 | Ab Science | 2-aminoaryloxazole compounds as tyrosine kinase inhibitors |
GB0326601D0 (en) | 2003-11-14 | 2003-12-17 | Novartis Ag | Organic compounds |
WO2005073225A1 (en) | 2004-01-30 | 2005-08-11 | Ab Science | 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors |
DE602005015742D1 (de) * | 2004-10-22 | 2009-09-10 | Janssen Pharmaceutica Nv | Aromatische amide als hemmer der c-fms-kinase |
NZ555289A (en) | 2004-10-22 | 2010-10-29 | Janssen Pharmaceutica Nv | Inhibitors of c-fms kinase |
US7645755B2 (en) | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
CN101437514B (zh) | 2004-10-22 | 2012-04-25 | 詹森药业有限公司 | C-fms激酶抑制剂 |
US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
US20060281755A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
US20060281788A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
AU2006304897B2 (en) | 2005-10-18 | 2012-07-12 | Janssen Pharmaceutica N.V. | Method of inhibiting FLT3 kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
CA2650057C (en) | 2006-04-20 | 2014-07-29 | Janssen Pharmaceutica N.V. | Phenyl- or pyridinyl-amide as inhibitors of c-fms kinase |
CA2649736C (en) | 2006-04-20 | 2013-11-26 | Janssen Pharmaceutica N.V. | Heterocyclic compounds as inhibitors of c-fms kinase |
EP2687516A1 (en) | 2006-04-20 | 2014-01-22 | Janssen Pharmaceutica N.V. | Inhibitors of C-FMS Kinase |
JP2008122527A (ja) | 2006-11-09 | 2008-05-29 | Nec Electronics Corp | 光トランシーバモジュールおよびその製造方法 |
EA016615B1 (ru) * | 2007-06-01 | 2012-06-29 | Басф Се | Способ получения n-замещенных (3-дигалометил-1-метилпиразол-4-ил)карбоксамидов |
EP2048126A1 (de) * | 2007-10-11 | 2009-04-15 | Bayer Schering Pharma AG | Benzocycloheptanderivate als selektiv wirksame Estrogene |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
WO2009058968A2 (en) | 2007-10-31 | 2009-05-07 | Janssen Pharmaceutica N.V. | Biomarker for assessing response to fms treatment |
BR112012017310A2 (pt) * | 2010-01-15 | 2016-04-19 | Janssen Pharmaceuticals Inc | derivados de triazol substituídos como moduladores de gama secretase |
CN103003262A (zh) * | 2010-07-16 | 2013-03-27 | 协和发酵麒麟株式会社 | 含氮芳香族杂环衍生物 |
-
2012
- 2012-08-07 JO JOP/2018/0012A patent/JOP20180012A1/ar unknown
-
2013
- 2013-08-05 JP JP2015526603A patent/JP6290884B2/ja active Active
- 2013-08-05 EP EP16172842.3A patent/EP3091006B1/en active Active
- 2013-08-05 EP EP13748242.8A patent/EP2882744B8/en active Active
- 2013-08-05 WO PCT/US2013/053602 patent/WO2014025679A1/en active Application Filing
- 2013-08-05 US US13/959,158 patent/US9029352B2/en active Active
- 2013-08-05 AU AU2013299926A patent/AU2013299926B2/en active Active
- 2013-08-05 IN IN660DEN2015 patent/IN2015DN00660A/en unknown
- 2013-08-05 CN CN201710504413.7A patent/CN107266405A/zh active Pending
- 2013-08-05 CN CN201380041841.0A patent/CN104520295B/zh active Active
- 2013-08-05 ES ES16172842.3T patent/ES2658773T3/es active Active
- 2013-08-05 ES ES13748242.8T patent/ES2607807T3/es active Active
- 2013-08-06 TW TW102128026A patent/TWI608004B/zh not_active IP Right Cessation
- 2013-08-06 JO JOP/2013/0237A patent/JO3248B1/ar active
- 2013-08-06 TW TW106125831A patent/TWI646090B/zh active
- 2013-08-07 AR ARP130102808A patent/AR092070A1/es active IP Right Grant
- 2013-08-07 UY UY0001034972A patent/UY34972A/es unknown
-
2015
- 2015-05-06 US US14/705,457 patent/US20150232439A1/en not_active Abandoned
- 2015-10-14 HK HK15110017.1A patent/HK1209418A1/xx not_active IP Right Cessation
- 2015-11-19 HK HK15111400.4A patent/HK1210616A1/xx not_active IP Right Cessation
-
2017
- 2017-03-01 AU AU2017201415A patent/AU2017201415C1/en active Active
-
2019
- 2019-11-06 AR ARP190103246A patent/AR117002A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP6290884B2 (ja) | 2018-03-07 |
TWI608004B (zh) | 2017-12-11 |
EP2882744B1 (en) | 2016-09-21 |
TWI646090B (zh) | 2019-01-01 |
CN107266405A (zh) | 2017-10-20 |
WO2014025679A1 (en) | 2014-02-13 |
EP2882744B8 (en) | 2016-11-09 |
ES2658773T3 (es) | 2018-03-12 |
JO3248B1 (ar) | 2018-09-16 |
TW201741292A (zh) | 2017-12-01 |
JP2015524471A (ja) | 2015-08-24 |
ES2607807T3 (es) | 2017-04-04 |
EP3091006A1 (en) | 2016-11-09 |
AU2013299926A1 (en) | 2015-05-21 |
AR117002A2 (es) | 2021-06-30 |
US9029352B2 (en) | 2015-05-12 |
CN104520295A (zh) | 2015-04-15 |
HK1210616A1 (en) | 2016-04-29 |
JOP20180012A1 (ar) | 2019-01-30 |
UY34972A (es) | 2014-02-28 |
US20150232439A1 (en) | 2015-08-20 |
EP2882744A1 (en) | 2015-06-17 |
IN2015DN00660A (xx) | 2015-06-26 |
AR092070A1 (es) | 2015-03-18 |
EP3091006B1 (en) | 2018-01-17 |
TW201408664A (zh) | 2014-03-01 |
AU2013299926B2 (en) | 2017-06-01 |
AU2017201415A1 (en) | 2017-03-16 |
CN104520295B (zh) | 2017-07-18 |
AU2017201415B2 (en) | 2019-01-03 |
AU2017201415C1 (en) | 2019-05-23 |
US20140045789A1 (en) | 2014-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263262B (en) | Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation | |
HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
EP2685992A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
HK1207384A1 (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d- ribofuranosyl nucleoside compounds 2--2--2--d- | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
EP2847186A4 (en) | SUBSTITUTED AMINOCHINAZOLINES USE AS CHINESE HEMMER | |
HK1205097A1 (en) | Process for the production of methylbutinol | |
HK1210616A1 (en) | Process for the preparation of c-fms kinase inhibitors c-fms | |
IL236450A (en) | Process for making 5-fluoro-h1-pyrazoles | |
PL399419A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
PL399418A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
AP2015008532A0 (en) | Syk kinase inhibitors as treatment for malaria | |
EP2885302A4 (en) | PROCESS FOR THE PREPARATION OF DIPEPTIDYLPEPTIDASE INHIBITORS | |
HK1210225A1 (en) | Procedure for the production of tiacumicin | |
ZA201405824B (en) | Process for the preparation of substituted phenylpropanones | |
HK1214825A1 (zh) | 用於製備 -氰基- 吡啶- -基 乙基 -甲基硫亞胺的改善方法 | |
IL229669A0 (en) | Process for the preparation of 1,2,3 triazole 4 carboxamide | |
IL234440A0 (en) | Process for the production of nitroalcohols | |
HUP1200675A2 (en) | Process for the preparation of pyrimidinyl-piperazines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230803 |